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Abstract
Background: Idiopathic Parkinson’s disease (IPD) and LRRK2-associated PD (LRRK2-PD) might be expected to differ clinically
since the neuropathological substrate of LRRK2-PD is heterogeneous. The range and severity of extra-nigral nonmotor
features associated with LRRK2 mutations is also not well-defined.
Objective: To evaluate the prevalence and time of onset of nonmotor symptoms (NMS) in LRRK2-PD patients.
Methods: The presence of hyposmia and of neuropsychiatric, dysautonomic and sleep disturbances was assessed in 33
LRRK2-G2019S-PD patients by standardized questionnaires and validated scales. Thirty-three IPD patients, matched for age,
gender, duration of parkinsonism and disease severity and 33 healthy subjects were also evaluated.
Results: University of Pennsylvania Smell Identification Test (UPSIT) scores in LRRK2-G2019S-PD were higher than those in
IPD (23.566.8 vs 18.466.0; p = 0.002), and hyposmia was less frequent in G2019S carriers than in IPD (39.4% vs 75.8%;
p = 0.01). UPSIT scores were significantly higher in females than in males in LRRK2-PD patients (26.964.7 vs 19.466.8; p,
0.01). The frequency of sleep and neuropsychiatric disturbances and of dysautonomic symptoms in LRRK2-G2019S-PD was
not significantly different from that in IPD. Hyposmia, depression, constipation and excessive daytime sleepiness, were
reported to occur before the onset of classical motor symptoms in more than 40% of LRRK2-PD patients in whom these
symptoms were present at the time of examination.
Conclusion: Neuropsychiatric, dysautonomic and sleep disturbances occur as frequently in patients with LRRK2-G2019S-PD
as in IPD but smell loss was less frequent in LRRK2-PD. Like in IPD, disturbances such as hyposmia, depression, constipation
and excessive daytime sleepiness may antedate the onset of classical motor symptoms in LRRK2-G2019S-PD.
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Introduction
Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are
the most common cause of inherited parkinsonism and account for
a significant proportion of familial and sporadic Parkinson’s
disease (PD) cases [1–2]. The neuropathological substrate in
LRRK2-PD is in some cases quite different from idiopathic PD
(IPD) and ranges from brainstem or diffuse Lewy body pathology,
to nigral degeneration without distinctive histopathology, and to
progressive supranuclear palsy–like pathology. Age at disease onset
and parkinsonian motor features are similar between LRRK2
related PD (LRRK2-PD) and idiopathic PD (IPD) [3] but studies
assessing nonmotor symptoms (NMS) in LRRK2-PD patients are
limited and results at times conflicting [4–6]. Dysautonomia, sleep
and mood disturbances as well as other common NMS occurring
in IPD result, in part, from extra-nigral lesions in the brain and the
peripheral autonomic nervous system [7]. The heterogeneous
neuropathology of LRRK2-PD suggests that the range and
severity of extra-nigral NMS could differ from those encountered
in IPD.
The aim of the present study was to evaluate the prevalence and
estimate the onset of NMS in patients with LRRK2 G2019S PD.
Methods
Subjects
A sample of 1251 PD patients from two regions of Spain,
Catalonia (Hospital Clı́nic de Barcelona, Hospital Mútua de
Terrassa, Hospital Vall d’Hebron and Hospital de Bellvitge) and
Cantabria (Hospital Marqués de Valdecilla, Santander) was
screened for LRRK2 G2019S and codon 1441 (R1441G/C/H)
mutations as previously described [3]. PD was diagnosed
according to UK Parkinson’s Disease Society criteria [8]. LRRK2
G2019S carriers were proposed to participate in this study.
LRRK2-PD patients that met diagnostic criteria for dementia in
PD (PDD) [9] were excluded, to avoid interference of cognitive
impairment in the evaluation of NMS. A group of 33 IPD patients
were recruited as controls among those from the initial sample of
1180 patients that tested negative for LRRK2 mutations. We
selected prospectively on a case by case basis those patients who
matched to the LRRK2 subjects for age, gender, duration of
parkinsonism (from onset of motor symptoms, OMS) and disease
severity (Hoehn and Yahr (H-Y) stage), agreed to participate in the
study, did not fulfil criteria for PDD [9], and had not family
history for PD. We also studied age and gender matched healthy
subjects (HS) without PD, dementia, any other neurological
disorder or a positive family history for PD. Patients, their relatives
as well as medical staff of participating centre recruited volunteers
from their personal relations who were screened for exclusion
criteria and were enrolled as controls for this study. The study was
approved by the Hospital Clinic of Barcelona ethics committee
and the written informed consent was obtained from all study
subjects.
Parkinsonism evaluation
Information about motor symptoms (rest tremor, bradykinesia,
rigidity, postural instability and persistent asymmetry), as well as
development of levodopa-induced motor complications, freezing
of gait and repeated falls during the disease course, was collected
by means of a structured clinical interview. All patients were
assessed through the Unified Parkinson’s Disease Rating Scale
(UPDRS), Schwab & England scale and H-Y stage in On
condition. Medications at the time of the evaluation were also
recorded and levodopa equivalent daily dose (LEDD) calculated
[10].
Nonmotor symptoms evaluation
The presence of the following NMS was assessed: hyposmia;
neuropsychiatric disorders: depression, anxiety, hallucinations and
psychosis; dysautonomic symptoms: constipation and urinary
dysfunction; and sleep disturbances: REM Sleep Behaviour
Disorder (RBD), excessive daytime sleepiness (EDS) and insomnia.
A structured clinical interview was conducted to determine the
presence of each NMS at the time of the evaluation. When a NMS
was present, we asked the patient to estimate when it had been
developed in relation to the OMS (e.g. before, concurrently or
after). Each NMS was also evaluated by using several self-
administered tests. Information on the current use of medications,
such as laxatives, hypnotics or antidepressants to treat some of
these NMS, was also collected.
Smell loss was assessed by asking to the subjects whether they
experienced a loss or change in their ability to smell. The 40-items
University of Pennsylvania Smell Identification Test (UPSIT;
Smell Identification TestTM Sensonics, Spanish version) [11] was
administered. Factors that could impair odor identification, such
as active smoking habit, past-history of significant traumatic head
injury or rhinologic disorders, were also considered. UPSIT scores
obtained previously from 148 HS aged 30 to 85 year-old were used
for comparison with LRRK2-PD and IPD. Since odor identifica-
tion has been shown to decline with age and is better in females
than in males [11–12], these 148 HS were stratified by age (,50
years, n = 36; 50–69 years, n = 76; and $70, n = 36) and gender
(males, n = 73; females, n = 75). Mean and standard deviation (SD)
UPSIT score for each age-gender HS subgroup was calculated.
Hyposmia was considered to be present if the UPSIT score was
lower than the mean–2SD corresponding to the age-gender
matched HS subgroup.
Presence of depression and anxiety at the time of this study were
diagnosed according to DSM-IV criteria [13]. In addition, a
previous history of depression or anxiety was also recorded. The
Hospital Anxiety and Depression scale (HADS) [14] was used to
quantify the symptoms. To assess the presence of hallucinations
and psychosis the NINS-NIMH work group criteria for psychosis
in PD [15] and the Parkinsonian Psychosis Rating Scale (PPRS)
were used [16].
Constipation was diagnosed according to the Rome criteria
[17]. Bowel movements frequency was evaluated. The Bristol
Scale Stool was used to assess whole gut transit time [18]. Urinary
dysfunction was assessed by asking for long-lasting complaints of
urinary urgency, frequency, incontinence or incomplete emptying.
The SCOPA-AUT was administered [19].
RBD was considered to be present when a history of
problematic sleep behaviors that were potentially harmful,
disrupted sleep continuity or was annoying to self or bed partner
was present [20]. EDS occurred when the subject could fall asleep
at least twice a day and the total sleeping time during the daytime
was more than 1 hour [21] and insomnia when there were long-
lasting complaints of difficulty in initiating or maintaining sleep.
The Pittsburgh sleep quality index (PSQI), the Epworth sleepiness
scale (ESS) and the Parkinson’s disease sleep scale (PDSS) were
administered [22–24].
Statistical analyses. Categorical variables and the frequency
of each NMS in the different groups were assessed by using the
Chi-square test or the Fisher’s exact test when appropriated. For
continuous variables, the Kruskal-Wallis analysis and the Mann-
Whitney U test were used to compare the means of groups for
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multiple comparisons and in pairs, respectively. To determine
whether there was a relationship between each NMS and other
variables, the Spearman correlation coefficient was obtained. A
significance level of ,0.05 was used. P-values were also calculated
using the false discovery rate (FDR) correction for multiple
comparisons. The statistical analyses were performed using
commercially available software (SPSS, Version18.0).
Results
General demographic data and parkinsonian motor
symptoms
Among 66 PD patients identified as LRRK2 G2019S carriers,
only 33 were included in the study (22 from Barcelona and 11
from Santander). One LRRK2-PD patient was excluded because
of severe dementia. Of the remaining 32 non-participants, 10
declined to participate, 11 had died when the study was initiated
and 11 had been lost for follow up. Thirty-three IPD patients and
33 HS (22 from Barcelona and 11 from Santander in each group)
were included. Mean age was not statistically different between
LRRK2-PD, IPD and HS (Table 1). Family history for PD was
positive in 20 (60.6%) of LRRK2-PD patients. There were no
significant differences in the features of motor symptoms, or in
dopamine replacement treatment (Table 1).
Nonmotor symptoms
Olfaction. Awareness of smell loss occurred in a similar
frequency in both LRRK2-PD and IPD patients (54.5% vs 63.6%;
p = 0.45; Table 2) and more frequently than in HS. Mean UPSIT
scores, though, were significantly different among the three
groups. LRRK2-PD patients had a mean UPSIT score signifi-
cantly higher than IPD patients (23.566.8 vs 18.466.0; p = 0.002)
and lower than HS (29.564.3; p = 0.001) (Figure 1. A). Hyposmia
was present in 13 (39.4%) of G2019S carriers, significantly lower
than in IPD (25 (75.8%); p = 0.01) (Table 2). No significant
differences were found in the frequency of active smoking,
rhinologic pathology or history of head trauma between groups.
Mean UPSIT score in LRRK2-PD cases was significantly
higher in females than in males (26.964.7 vs 19.466.8, p,0.01;
Figure 1.B). Hyposmia was present in only 3 (16.7%) LRRK2-PD
females, in contrast to 10 (66.7%) LRRK2-PD males. Such
significant difference in UPSIT scores by gender was not observed
in IPD patients (18.665.8 males vs 18.266.3 females; p = 0.66) or
HS (28.164.9 males vs 30.763.4 females; p = 0.10). LRRK2-PD
females were significantly older than LRRK2-PD males (67.868.9
vs 61.1613.3; p = 0.04), but disease duration or severity, and
frequency of active smoking, rhinologic pathology or history of
head trauma, were similar in both genders. Mean UPSIT score in
LRRK2-PD females was significantly higher than in IPD females
(p,0.01) and significantly lower than in HS females (p = 0.01). In
contrast, mean UPSIT score in LRRK2-PD males was similar to
Table 1. General demographic data and parkinsonian motor symptoms in patients with LRRK2 G2019S associated Parkinson’s
disease, idiopathic Parkinson’s disease and healthy subjects.
LRRK2 PD (n=33) IPD (n=33) HS (n=33) P
Age (years)1 64.8611.4 65.1610.0 64.8610.2 0.99"
Sex (male, %) 15 (45.4%) 15 (45.4%) 15 (45.4%) 1.0#
Disease duration (years)1 9.265.7 (2–28) 9.066.1 (1–30) 0.791
Motor symptoms during disease course; n (%)
Rest tremor 29 (87.9%) 27 (81.8%) 0.49#
Action tremor 20 (60.6%) 23 (69.7%) 0.44#
Bradykinesia 33 (100%) 33 (100%) 1.06
Postural instability 16 (48.5%) 11 (33.3%) 0.21#
Repeated falls 9 (27.3%) 7 (21.2%) 0.57#
Freezing of gait 18 (54.6%) 14 (42.4%) 0.32#
Persistent Asymmetry 31 (93.9%) 31 (93.9%) 1.06
Fluctuations 18 (54.5%) 17 (51.5%) 0.80#
Dyskinesias 19 (57.6%) 16 (48.5%) 0.46#
UPDRS part II1 10.367.5 (0–26) 8.364.9 (0–24) 0.481
UPDRS part III1 24.0614.0 (0–62) 19.9612.2 (2–62) 0.161
UPDRS part IVA+IVB1 3.2163.7 (0–13) 2.062.7 (0–10) 0.181
Hoehn & Yahr stage1 2.161.0 (1–4) 1.860.8 (1–4) 0.241
Schwab & England1 82.1614.7 (50–100) 85.8610.3 (60–100) 0.441
Treatment with levodopa; n (%) 31 (93.9%) 30 (90.9%) 1.06
Treatment with dopamine agonists; n (%) 27 (81.8%) 25 (75.8%) 0.55#
Levodopa equivalent daily dose (in mg)1 793.76482.1 (105–2744) 823.06516.4 (0–1770) 0.771
LRRK2 G2019S PD: LRRK2 G2019S related Parkinson’s disease; IPD: Idiopathic Parkinson’s disease; HS: healthy subjects.
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Figure 1. University of Pennsylvania Smell Identification Test (UPSIT) scores. UPSIT scores in LRRK2 G2019S Parkinson’s disease patients,
idiopathic Parkinson’s disease patients and healthy controls (Figure 1.A). UPSIT score in each group separated by sex (Figure 1.B). Circles represent
individual values, while the bar refers to the mean UPSIT score in each group. IPD: idiopathic Parkinson’s disease; LRRK2-PD: LRRK2 associated
Parkinson’s disease, HS: healthy subjects.
doi:10.1371/journal.pone.0108982.g001
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IPD males (p = 0.71), and significantly lower than in HS males (p,
0.01). No correlation was found between UPSIT score and disease
duration or severity in LRRK2-PD or IPD patients.
Neuropsychiatric symptoms. Current active depression
and current treatment with antidepressive drugs were more
frequent in IPD than in LRRK2-PD, but these differences were
not statistically significant (Table 2). There were no differences in
the frequency of anxiety disorder between LRRK2-PD, IPD and
HS. Nine IPD patients were under antidepressive treatment but
only 8 had active depression. Similarly, 3 LRRK2-PD patients
were under anxiety treatment but only 2 had active anxiety. These
patients were treated with antidepressants and benzodiazepines
because of past history of depression and anxiety despite
improvement of symptoms. The HADS subscore for depression
was similar between LRRK2-PD and IPD, but higher than HS.
The HADS subscore for anxiety was similar between groups
(Table 2). Hallucinations occurred in similar frequency in
LRRK2-PD and IPD. In all LRRK2 and IPD patients,
hallucinations were visual in nature. Delusions or severe psychosis
did not occur in any LRRK2-PD nor IPD patient.
Dysautonomic symptoms. No significant differences were
found in the presence of constipation between LRRK2-PD, IPD
and HS groups (Table 2). Mean Bristol scale stool score was
significantly higher in LRRK2-PD than in IPD (Table 2). Mean
SCOPA-AUT subscore for gastro-intestinal dysfunction was
similar in LRRK2-PD and IPD. IPD patients, but not LRRK2-
PD patients, showed mean SCOPA-AUT subscore for gastro-
intestinal dysfunction significantly higher compared to HS. The
presence of urinary dysfunction was not statistically different
between three groups. No differences in mean SCOPA-AUT
subscore for urinary dysfunction was identified among the three
groups (Table 2).
Sleep disturbances. A trend to an increased frequency of
RBD symptoms in IPD compared to LRRK2-PD was found.
Frequency of insomnia and use of hypnotics were similar among
the three groups. IPD patients had a borderline increased
frequency of EDS compared to LRRK2-PD (Table 2). Mean
Global PSQI, total PDSS and EDSS scores were not significantly
different between LRRK2-PD and IPD. LRRK2-PD and IPD
patients had a mean Global PSQI score that was not significantly
different from HS. In contrast, LRRK2-PD and IPD patients
showed a mean total PDSS significantly lower than HS. Mean
ESS score in LRRK2 and IPD were significantly higher compared
to HS (Table 2).
Estimated onset of NMS in LRRK2-PD
LRRK2-PD patients frequently reported that several NMS
occurred before OMS (table 3). Smell loss, depression, constipa-
tion and EDS were reported to develop before OMS in more than
40% of the LRRK2-PD patients in whom these symptoms were
present at the time of examination. Smell loss and depression were
reported to occur at variable time intervals before OMS but
constipation and EDS frequently were estimated to occur more
than 10 years before OMS in most LRRK2-PD (Table 3). In
LRRK2-PD subjects, RBD was reported to occur usually
coincidentally or after OMS. In IPD patients smell loss, depression
and constipation were also reported to appear before OMS, but
EDS and RBD were reported to appear coincidentally or after
OMS in most cases. Anxiety symptoms were reported coinciden-
tally or developing after OMS in most LRRK2-PD cases but more
frequently before OMS in IPD.
Discussion
Our study shows that NMS occur frequently in LRRK2
G2019S PD patients, in a frequency similar to a group of IPD
subjects of similar disease duration, severity of motor symptoms,
and dopaminergic treatment. The only NMS that significantly
differed between LRRK2-PD and IPD was smell loss. While
reported awareness of smell loss occurred as frequently in LRRK2-
PD as in IPD, UPSIT scores were significantly higher in LRRK2-
PD. Hyposmia was present in only 39% of our LRRK2-PD
patients, in contrast to 75% of IPD patients. Also in other studies
the prevalence of abnormal olfaction in LRRK2-PD has been
found to range from 36 to 49%, significantly inferior to IPD (75–
81%) [5].
Reasons for the differences in smell between LRRK2-PD and
IPD encountered in this and other studies remain unclear.
Heterogeneous pathology or less severe involvement of olfactory
structures in LRRK2-PD has been proposed to explain such
differences. In Parkin gene associated PD, absence of smell loss is
common [25] and neuropathological changes are usually limited
to the substantia nigra without LB pathology [26]. One study
involving four LRRK2-PD brains, reported a-synuclein accumu-
lation in the olfactory bulb, olfactory tract, and primary olfactory
cortex providing a pathophysiologic substrate for olfactory deficit6.
Still only 20% of LRRK2 G2019S cases are thought to present
different pathology to that seen in IPD [27], and therefore
neuropathological heterogeneity may not adequately explain the
preservation of the olfactory sense in most LRRK2 patients.
In contrast to previous studies, we found that smell was
particularly preserved in G2019S LRRK2-PD females. Such
difference could suggest a gender effect in the expression of
LRRK2-PD. Gender-related susceptibility factors likely play a role
in PD, a disorder more common in males [28] and female
predominance has been suggested to occur in G2019S LRRK2-
PD [29]. One study has also reported an earlier age at disease
onset in women than in men with the G2019S mutation [4].
Neuropsychiatric disorders, dysautonomic symptoms and sleep
disturbances were frequent in LRRK2 G2019S carriers, similarly
to that observed in IPD. Depression, anxiety and hallucinations
were present in our LRRK2 patients at a frequency similar to that
reported in the literature [4,30,31]. Sleep disturbances like RBD,
insomnia and EDS are common in PD and have been reported to
be present frequently in patients carrying the G2019S mutation.
The frequency of RBD symptoms tended to be lower in LRRK2-
PD cases than in IPD, although the difference was not statistically
significant. The prevalence of RBD in IPD reported in the
literature varies from 15% to 46% [32]. A recent study has
reported RBD symptoms in only 11% of the LRRK2-PD patients,
compared to 42% of IPD patients [33], suggesting that RBD could
be less frequently present in LRRK2-PD. Frequency of constipa-
tion and urinary dysfunction in our LRRK2 patients was similar to
that reported by others [5,31,33]. In our study the frequency of
constipation was similar between LRRK2 and IPD, but mean
Bristol scale stool score was significantly lower in LRRK2-PD than
in IPD, suggesting that intestinal motility could be less impaired in
LRRK2-PD.
A substantial proportion of our LRRK2-PD patients reported
that several NMS, such as hyposmia, depression, constipation, or
EDS, had been present before OMS. Some NMS have been
evaluated in a limited number of asymptomatic subjects carrying
the LRRK2 G2019S mutation [6,31,34] and hyposmia, depres-
sion and constipation have been found to occur in some non-
manifesting carriers [31,34], although some of these premotor
features were found to be no more frequent in non-manifesting
Nonmotor Symptoms in LRRK2 Parkinson’s Disease
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Table 3. Estimated presence of nonmotor symptoms in LRRK2 G2019S Parkinson’s disease patients and idiopathic Parkinson’s
disease patients in relation to onset of motor symptoms.
LRRK2-PD IPD
Loss or change in smell sense; n 18 21
Coincidentally or after OMS (n;%) 8 (44.4%) 8 (38.1%)
Before OMS (n;%) 8 (44.4%) 8 (38.1%)
More than 10 yrs before OMS 2/8 (25%) 4/8 (50%)
Within 10 yrs before OMS 4/8 (50%) 2/8 (25%)
Within 2 yrs before OMS 2/8 (25%) 2/8 (25%)
Unknown 2 (11.1%) 5 (23.8%)
Depression; n 19 12
Coincidentally or after OMS (n;%) 11 (57.9%) 7 (58.3%)
Before OMS (n;%) 8 (42.1%) 5 (41.7%)
More than 10 yrs before OMS 2/8 (25%) 2/5 (40%)
Within 10 yrs before OMS 3/8 (37.5%) 2/5 (40%)
Within 2 yrs before OMS 3/8 (37.5%) 1/5 (20%)
Anxiety symptoms; n 8 9
Coincidentally or after OMS (n;%) 6 (75%) 1 (11.1%)
Before OMS (n;%) 2 (25%) 8 (88.9%)
More than 10 yrs before OMS 0 5/8 (62.5%)
Within 10 yrs before OMS 0 3/8 (37.5%)
Within 2 yrs before OMS 2/2 (100%) 0
Constipation; n 14 15
Coincidentally or after OMS (n;%) 5 (35.7%) 8 (53.3%)
Before OMS (n;%) 9 (64.3%) 7 (46.7%)
More than 10 yrs before OMS 8/9 (88.9%) 7/7 (100%)
Within 10 yrs before OMS 1/9 (11.1%) 0
Within 2 yrs before OMS 0 0
Urinary dysfunction; n 17 15
Coincidentally or after OMS (n;%) 12 (70.6%) 12 (80%)
Before OMS (n;%) 5 (29.4%) 3 (20%)
More than 10 yrs before OMS 0 0
Within 10 yrs before OMS 1/5 (20%) 1/3 (33.3%)
Within 2 yrs before OMS 4/5 (80%) 2/3 (66.6%)
RBD symptoms; n 7 14
Coincidentally or after OMS (n;%) 5 (71.4%) 12 (85.7%)
Before OMS (n;%) 2 (28.6%) 2 (14.3%)
More than 10 yrs before OMS 0 0
Within 10 yrs before OMS K (50%) 0/2 (0.0%)
Within 2 yrs before OMS K (50%) 2/2 (100%)
Insomnia; n 19 22
Coincidentally or after OMS (n;%) 16 (84.2%) 14 (63.6%)
Before OMS (n;%) 3 (15.8%) 8 (36.4%)
More than 10 yrs before OMS 2/3 (66.6%) 6/8 (75%)
Within 10 yrs before OMS 0 0
Within 2 yrs before OMS 1/3 (33.3%) 2/8 (25%)
EDS; n 6 13
Coincidentally or after OMS (n;%) 3 (50%) 12 (92.3%)
Before OMS (n;%) 3 (50%) 1 (7.7%)
More than 10 yrs before OMS 2/3 (66.6%) 1/1 (100%)
Within 10 yrs before OMS 1/3 (33.3%) 0
Within 2 yrs before OMS 0 0
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carriers than in non-carriers. The presence of these symptoms in
the premotor phase, as in the case of IPD, suggests that the
neuropathological changes occur probably in non-dopaminergic
brainstem and peripheral nervous system structures before the
involvement of the substantia nigra, as suggested by Braak [35].
Some limitations of our study should be mentioned. Some
results are based on patient’s responses. More information could
be obtained with objective tests, as occurred in smell evaluation,
where no differences were identified when asked for a loss or
change in smell, while the UPSIT was able to detect significant
differences. Also since the mean disease duration was 9 years, we
acknowledge that the patient’s responses in regards to symptoms
occurring in the presymptomatic phase may not be accurate,but
others studies have reported NMS such as these occurring in the
premotor phase of LRRK2-PD [6,30]. Future prospective studies
in asymptomatic LRRK2 G2019S carriers should clarify this issue.
Finally, cognitive dysfunction which is among the most relevant
and disabling NMS in PD, was not assessed in detail in our study,
but only one patient was excluded for the study because of
dementia. Some studies have suggested that the frequency of
dementia could be lower than usually reported in IPD [5,36].
Cognitive dysfunction in LRRK2 patients deserves additional and
specifically designed studies. One strength of our study, in contrast
to previous ones that usually assessed one or only a few NMS,
include the evaluation of several NMS in the same group of
patients which has given a more global impression of the
contribution of NMS to the clinical picture of LRRK2 associated
PD. In addition, our study includes similar NMS assessments in a
group of healthy subjects for comparison purposes.
In summary, neuropsychiatric, dysautonomic and sleep distur-
bances are equally frequent in non-demented LRRK2 G2019S PD
and IPD. Olfactory dysfunction, however, occurs less often in
LRRK2 G2019S PD, maybe reflecting less involvement of
olfactory structures by the neurodegenerative process. Smell
function seems to be particularly preserved in females with the
G2019S mutation, suggesting a gender effect in the expression of
some LRRK2-PD symptoms. Some NMS may antedate the onset
of PD motor syndrome in substantial number of patients carrying
LRRK2 G2019S mutation, indicating that a premotor phase
similar to that occurring in IPD probably occurs in this genetic
form of PD, and that common physiopathological mechanism
probably underlie the onset and progression of the disease in both
LRRK2 G2019S PD and IPD.
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